G1 Therapeutics, Inc. (GTHX)
Pre-market:
| Previous close | 4.2800 |
| Open | 4.3100 |
| Bid | 4.1500 x 300 |
| Ask | 4.2100 x 100 |
| Day's range | 4.0350 - 4.3100 |
| 52-week range | 1.0800 - 5.0000 |
| Volume | |
| Avg. volume | 1,346,456 |
| Market cap | 217.672M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.50 |
GlobeNewswireG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m. ET. To register for the event and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 1
- GlobeNewswire
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET. The webcast of the event will be accessible on the Events & Presentations page of https://www.g1therapeutics.com/. About G1 TherapeuticsG1 Therapeutics, In
- GlobeNewswire
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 3,000 shares of G1’s common stock and 1,500 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to t
